Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: Effects of the i f current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale

Cardiovascular Drugs and Therapy

Volumn 23, Issue 3, 2009, Pages 243-247

  Dominguez Rodriguez, Alberto ^a   Fard, Sima Samimi ^a   Abreu Gonzalez, Pedro ^b   Bosa Ojeda, Francisco ^a   Consuegra Sanchez, Luciano ^c   Jiménez Sosa, Alejandro ^a   Grande, Alejandro Sánchez ^a   Kaski, Juan Carlos ^d  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute coronary syndromes; C reactive protein; Inflammation; Ivabradine

Indexed keywords

C REACTIVE PROTEIN; IVABRADINE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FOLLOW UP; HEART ARREST; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; HEART ARREST; HUMANS; INFLAMMATION; ION CHANNELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PATIENT ADMISSION;

EID: 67649090226     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6164-9     Document Type: Article

References (19)

1. T Ross 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 362 801 809
2. DR Morrow N Rifai EM Antman 1998 C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy J Am Coll Cardiol 31 1460 1465 (Pubitemid 28273285)
3. AN Phillips JD Neaton DG Cook 1992 Leukocyte count and risk of major coronary heart disease events Am J Epidemiol 136 59 70
4. PM Ridker M Cushman MJ Stampfer 1997 Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 973 979 (Pubitemid 27152782)
5. HV Huikuri TH Malkikallio KEJ Airaksinen 1998 Power-law relationship of heart rate variability as a predictor of mortality in the elderly Circulation 97 2031 2036 (Pubitemid 28243665)
6. H Tsuji MG Larson FJ Venditti 1996 Impact of heart rate variability on risk for cardiac events: the Framingham Heart Study Circulation 94 2850 2855 (Pubitemid 26411751)
7. HV Hikuri V Jokinen M Syvanne for the Lipid Coronary Angioplasty Trial (LOCAT) study Group 1999 Heart rate variability and progression of coronary atherosclerosis Arterioscler Thromb Vasc Biol 19 1979 1985 (Pubitemid 29379932)
8. WB Kannel CE Kannel R Paffenbarger 1987 Heart rate and cardiovascular mortality in the Framingham study Am Heart J 113 1489 1494 (Pubitemid 17092823)
9. A Sajadich OW Nielsen V Rasmussen 2004 Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease Eur Heart J 25 363 370 (Pubitemid 38391517)
10. UE Heidland BE Strauer 2001 Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption Circulation 104 1477 1482 (Pubitemid 32917338)
11. f ) in isolated mouse sino-atrial cells Cardiovasc Res 52 51 64 (Pubitemid 32835238)
12. P Bois J Bescond B Renaudon 1996 Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells Br J Pharmacol 118 1051 1057 (Pubitemid 26261281)
13. SM Gardiner PA Kemp JE March 1995 Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats Br J Pharmacol 115 579 586
14. JC Tardif I Ford M Tendera 2005 Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina Eur Heart J 26 2529 2536 (Pubitemid 41677303)
15. JS Borer K Fox P Jaillon 2003 Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double blind, multicentered, placebo-controlled trial Circulation 107 817 823 (Pubitemid 36241038)
16. F Custodis M Baumhakel N Schlimmer 2008 Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E deficient mice Circulation 117 2377 2387 (Pubitemid 351653554)
17. JP Bassand CW Hamm D Ardissino 2007 Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur Heart J 28 1598 1660 (Pubitemid 47227122)
18. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, et al. SIESTA Investigators. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. doi: 10.1016/j.atherosclerosis.2008.01.009.
19. PC O'Brien TR Fleming 1979 A multiple testing procedure for clinical trials Biometrics 35 549 556 (Pubitemid 10242750)